4 Result: FibroGen
Pharvaris Gains Momentum, Avalo Therapeutics and FibroGen Suffer Setbacks
June 26th, 2023
Shares of Pharvaris N.V. (Nasdaq: PHVS) surged over 10% in pre-market trading after the clinical-stage company announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application f. Read more
FibroGen Trial Disappoints, UnitedHealth Dividend Boost, Oracle and Ultragenyx Ratings Update
June 07th, 2023
FibroGen, Inc. (Nasdaq: FGEN) announced the topline data from the Phase 3 LELANTOS-1 trial, evaluating pamrevlumab as a treatment for non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. Unfortunately. Read more
Chijet Motor Debuts on Nasdaq, Market Experts Bullish on Ambrx, FibroGen, Bowlero, REGENXBIO and Kopin
June 02nd, 2023
Chijet Motor Company, Inc. (Nasdaq: CJET) achieved a significant milestone as it officially joined the ranks of NASDAQ-listed companies under the ticker symbol "CJET" on Friday. With a core focus on the development, manufacturing, sales, and. Read more
Monro Falls Short of Q4 Expectations as Micron Technology, Mullen Automotive, and FibroGen Make Positive Pre-Market Moves
May 18th, 2023
Monro, Inc. (Nasdaq: MNRO) has released its financial results for the fourth quarter of fiscal 2023, reporting adjusted earnings per share (EPS) that fell short of market expectations. The company's adjusted EPS for the quarter stood at $0.08, compar. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login